Nab-paclitaxel demonstrated superior activity vs paclitaxel in early breast cancer

the ONA take:

In the GeparSepto clinical trial sponsored by the German Breast Group (GBG), nab-paclitaxel (Abraxane) demonstrated significant benefit for patients with early high-risk breast cancer compared with conventional solvent-based paclitaxel. Researchers found a statistically significant and clinically meaningful 9% absolute improvement in pathological complete response (pCR) rate when neoadjuvant chemotherapy was started with nab-paclitaxel instead of paclitaxel followed by epirubicin/cyclophosphamide, all given before surgery. The nab-paclitaxel dose used in the study was 125 mg/m2 for most of the participants after an initial higher dose was reduced based on an interim safety analysis, which delivered 56% more chemotherapy to the tumor than conventional paclitaxel. The percentage of patients taking nab-paclitaxel who discontinued the treatment due to toxicities was higher compared with those patients taking paclitaxel (17% vs 6%); however, most patients did continue onto the next stage of treatment and surgery. “This is the first time in 18 years of GBG running neoadjuvant studies in collaboration with AGO-B [study group] that pCR rates could be strongly increased by replacing a key component of the standard neoadjuvant chemotherapy instead of just adding additional agents to it,” reported the chairman and managing director of GBG.

Nab-paclitaxel demonstrated superior activity vs paclitaxel in early breast cancer
Nab-paclitaxel demonstrated superior activity vs paclitaxel in early breast cancer
The German Breast Group (GBG) said nab-paclitaxel (ABRAXANE®) demonstrated significant benefit for patients with early high risk breast cancer when compared to conventional solvent-based paclitaxel.
READ FULL ARTICLE From Medical News Today
Loading links....
You must be a registered member of ONA to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs